Pfizer on Thursday named James List as the head of the drugmaker's Internal Medicine portfolio, which includes development of cardiovascular and obesity medicines.
PHILADELPHIA, March 05, 2025 (GLOBE NEWSWIRE) -- Berger Montague advises shareholders of Pfizer Inc. (“Pfizer” or the “Company”) (NYSE: PFE) about an investigation into Pfizer's Board of Directors for potential breaches of fiduciary duties to Pfizer and its shareholders in connection with the Company's marketing and sale of Depo-Provera.
Pfizer's revenue has stabilized, and operational efficiency is improving, supporting a "Strong buy" rating with a 6.5% forward dividend yield. The market sentiment in the next few months is likely to be quite positive for Pfizer, as the optimism around growth stocks is fading. Patent cliff risks exist, but Pfizer's substantial R&D investments and solid fundamentals make it a compelling high-yie...
Hyperinflation and high interest rates make dividend-paying stocks attractive, providing cash flow and alleviating inflation pressure. Pfizer's 6% yield is appealing despite recent stock declines, with a low forward multiple and management's commitment to maintaining dividends. Cost savings and Haleon share sales should support Pfizer's dividend yield, with free cash flow expected to improve ne...
If you want to generate significant long-term gains in the stock market, one place to start looking for investments is among the companies that Wall Street isn't all that thrilled with today. In the short term, these may not be good performers, and they may not have looked like great buys in recent months or years.
Shrewd investors know that bear markets open up great opportunities to pick up shares of excellent companies from the discount bin. However, even in a bull market, like the one we're currently experiencing, it's possible to find attractive companies to invest in at attractive prices.
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.